Review Article

Laboratory Diagnosis of Antiphospholipid Syndrome

Authors: Pramod Reddy, MD

Abstract

Antiphospholipid syndrome is an intriguing clinical entity encountered by all physicians because of the wide range of clinical manifestations involving every organ system. Ordering a single test under the name “antiphospholipid antibody” does not rule out this entity. There are overlapping but distinct autoantibodies, and a positive result in one assay is conclusive despite a negative result in another. Laboratories continue to conduct several nonstandard tests as part of integrated kits and physicians should be familiar with them for proper interpretation of the results. Lupus anticoagulant testing is an integral part of every thrombophilia workup and should be performed regardless of the screening activated partial thromboplastin time or mixing study.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Gresele P, Migliacci R, Vedovati MC. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res. 2009; 123: 444–451.
 
2. Dlott JS, Roubey RA. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep. 2012; 14: 71–78.
 
3. García-Carrasco M, Galarza-Maldonado C, Mendoza-Pinto C, et al. Infections and the antiphospholipid syndrome. Clin Rev Allergy Immunol. 2009; 36: 104–108.
 
4. Delbos V, Abgueguen P, Chennebault JM, et al. Acute cytomegalovirus infection and venous thrombosis: role of antiphospholipid antibodies. J Infect. 2007; 54: e47–e50.
 
5. Kiser KL, Badowski ME. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy. 2010; 30: 1292–1302.
 
6. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 2002; 46: 1019–1027.
 
7. Gris JC, Quéré I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nîmes Obstetricians and Haematologists Study—NOHA. Thromb Haemost. 2000; 84: 228–236.
 
8. Sugi T, Matsubayashi H, Inomo A, et al. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res. 2004; 30: 326–332.
 
9. de Groot PG, Urbanus RT. The significance of autoantibodies against β2-glycoprotein I. Blood. 2012; 120: 266–274.
 
10. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998; 95: 15542–15546.
 
11. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009; 7: 1767–1773.
 
12. Bertolaccini ML. Antibodies to prothrombin. Lupus. 2012; 21: 729–731.
 
13. Bertolaccini ML, Atsumi T, Koike T, et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost. 2005; 93: 289–297.
 
14. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005; 3: 1231–1238.
 
15. Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost. 2007; 5: 1158–1164.
 
16. Binder W, Lewis S, Shums Z. Clinical significance of IgG and IgM autoantibodies that target the complex of phosphatidylserine and prothrombin. Lupus. 2010; 19: C134[abstract]
 
17. Rand JH, Wu XX, Andree HA, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding tophospholipids: a “lupus procoagulant” phenomenon. Blood. 1998; 92: 1652–1660.
 
18. Tomer A, Bar-Lev S, Fleisher S, et al. Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool. Br J Haematol. 2007; 139: 113–120.
 
19. Rand JH, Wu XX, Lapinski R. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood. 2004; 104: 2783–2790.
 
20. de Laat B, Wu XX, van Lummel M, et al. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood. 2007; 109: 1490–1494.
 
21. Rand JH, Arslan AA, Wu XX, et al. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol. 2006; 194: 182–188.
 
22. Sahud M, Zhukov O, Mo K, et al. False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies. Haemophilia. 2012; 18: 777–781.
 
23. Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost. 2012; 38: 385–389.
 
24. Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. Semin Thromb Hemost. 2012; 38: 360–374.
 
25. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995; 74: 1185–1190.
 
26. Dembitzer FR, Suarez Y, Aledort LM, et al. Screening coagulation testing using the APTT: which reagent to choose? Am J Hematol. 2010; 85: 726
 
27. Devreese KM. Evaluation of a new silica clotting time in the diagnosis of lupus anticoagulants. Thromb Res. 2007; 120: 427–438.
 
28. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost. 1993; 70: 787–793.
 
29. Devreese KM. Evaluation of a new commercial dilute prothrombin time in the diagnosis of lupus anticoagulants. Thromb Res. 2008; 123: 404–411.
 
30. Martinuzzo M, Adamczuk Y, Varela ML, et al. The activated seven lupus anticoagulant (ASLA) test has comparable sensitivity to classical assays for screening of lupus anticoagulant. Thromb Haemost. 2005; 93: 1007–1009.
 
31. Forastiero R. Bleeding in the antiphospholipid syndrome. Hematology. 2012; 17: S153–S155.
 
32. Favaloro EJ, Reben R, Mohammed S, et al. A clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations. Intern Med J. 2012; 42: 427–434.
 
33. Liestøl S, Wisløff F. Effect of subcutaneous administration of dalteparin on lupus anticoagulant assays. Thromb Res. 2005; 115: 509–517.
 
34. Gosselin RC, King JH, Janatpur KA, et al. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med. 2004; 128: 1142–1145.
 
35. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology. 2011; 43: 682–692.
 
36. Kershaw G, Suresh S, Orellana D, et al. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost. 2012; 38: 375–384.
 
37. van Os GM, de Laat B, Kamphuisen PW, et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost. 2011; 9: 1657–1659.
 
38. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009; 7: 1737–1740.
 
39. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4: 295–306.
 
40. Jennings I, Kitchen S, Kitchen DP, et al. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories? J Thromb Haemost. 2011; 9: 2117–2119.
 
41. Cervera R, Conti F, Doria A, et al. Does seronegative antiphospholipid syndrome really exist? Autoimmun Rev. 2012; 11: 581–584.
 
42. Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, et al. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’). Ann Rheum Dis. 2012; 71: 242–244.